Found 11 results
Author Title [ Type(Asc)] Year
Filters: Author is Antin, Joseph H  [Clear All Filters]
Journal Article
J. Bolaños-Meade, Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., Bin Chen, Y. -, Damon, L. E., Efebera, Y. A., Geller, N. L., Giralt, S. A., Hari, P., Holtan, S. G., Horowitz, M. M., Jacobsohn, D. A., Jones, R. J., Liesveld, J. L., Logan, B. R., MacMillan, M. L., Mielcarek, M., Noel, P., Pidala, J., Porter, D. L., Pusic, I., Sobecks, R., Solomon, S. R., Weisdorf, D. J., Wu, J., Pasquini, M. C., and Koreth, J., Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with, Lancet Haematol, vol. 6, no. 3, pp. e132-e143, 2019.
C. Cutler, Logan, B., Nakamura, R., Johnston, L., Choi, S., Porter, D., Hogan, W. J., Pasquini, M., MacMillan, M. L., Hsu, J. W., Waller, E. K., Grupp, S., McCarthy, P., Wu, J., Hu, Z. - H., Carter, S. L., Horowitz, M. M., and Antin, J. H., Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT., Blood, vol. 124, no. 8, pp. 1372-7, 2014.
C. Cutler, Stevenson, K., Kim, H. T., Richardson, P., Ho, V. T., Linden, E., Revta, C., Ebert, R., Warren, D., Choi, S., Koreth, J., Armand, P., Alyea, E., Carter, S., Horowitz, M., Antin, J. H., and Soiffer, R., Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation., Blood, vol. 112, no. 12, pp. 4425-31, 2008.
S. R. Walsh, Wilck, M. B., Dominguez, D. J., Zablowsky, E., Bajimaya, S., Gagne, L. S., Verrill, K. A., Kleinjan, J. A., Patel, A., Zhang, Y., Hill, H., Acharyya, A., Fisher, D. C., Antin, J. H., Seaman, M. S., Dolin, R., and Baden, L. R., Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial., J Infect Dis, vol. 207, no. 12, pp. 1888-97, 2013.
J. Pidala, Hamadani, M., Dawson, P., Martens, M., Alousi, A. M., Jagasia, M., Efebera, Y. A., Chhabra, S., Pusic, I., Holtan, S. G., Ferrara, J. L. M., Levine, J. E., Mielcarek, M., Anasetti, C., Antin, J. H., Bolaños-Meade, J., Howard, A., Logan, B. R., Leifer, E. S., Pritchard, T. S., Horowitz, M. M., and MacMillan, M. L., Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial., Blood, vol. 135, no. 2, pp. 97-107, 2020.
M. Abu Zaid, Wu, J., Wu, C., Logan, B. R., Yu, J., Cutler, C., Antin, J. H., Paczesny, S., and Choi, S. Won, Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT., Blood, vol. 129, no. 2, pp. 162-170, 2017.
K. Ballen, Mendizabal, A. M., Cutler, C., Politikos, I., Jamieson, K., Shpall, E. J., Dey, B. R., Attar, E., McAfee, S., Delaney, C., McCarthy, P., Ball, E. D., Kamble, R., Avigan, D., Maziarz, R. T., Ho, V. T., Koreth, J., Alyea, E., Soiffer, R., Wingard, J. R., Boussiotis, V., Spitzer, T. R., and Antin, J. H., Phase II trial of parathyroid hormone after double umbilical cord blood transplantation., Biol Blood Marrow Transplant, vol. 18, no. 12, pp. 1851-8, 2012.
J. Bolaños-Meade, Logan, B. R., Alousi, A. M., Antin, J. H., Barowski, K., Carter, S. L., Goldstein, S. C., Hexner, E. O., Horowitz, M. M., Lee, S. J., Levine, J. E., MacMillan, M. L., Martin, P. J., Mendizabal, A. M., Nakamura, R., Pasquini, M. C., Weisdorf, D. J., Westervelt, P., and Ho, V. T., Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802., Blood, vol. 124, no. 22, pp. 3221-7; quiz 3335, 2014.
J. Tolar, H Deeg, J., Arai, S., Horwitz, M., Antin, J. H., McCarty, J. M., Adams, R. H., Ewell, M., Leifer, E. S., Gersten, I. D., Carter, S. L., Horowitz, M. M., Nakamura, R., Pulsipher, M. A., Difronzo, N. L., Confer, D. L., Eapen, M., and Anderlini, P., Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels., Biol Blood Marrow Transplant, vol. 18, no. 7, pp. 1007-11, 2012.
M. C. Pasquini, Logan, B., Jones, R. J., Alousi, A. M., Appelbaum, F. R., Bolaños-Meade, J., Flowers, M. E. D., Giralt, S., Horowitz, M. M., Jacobsohn, D., Koreth, J., Levine, J. E., Luznik, L., Maziarz, R., Mendizabal, A., Pavletic, S., Perales, M. - A., Porter, D., Reshef, R., Weisdorf, D., and Antin, J. H., Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials., Biol Blood Marrow Transplant, vol. 24, no. 6, pp. 1274-1280, 2018.
A. Krishnan, Pasquini, M. C., Logan, B., Stadtmauer, E. A., Vesole, D. H., Alyea, E., Antin, J. H., Comenzo, R., Goodman, S., Hari, P., Laport, G., Qazilbash, M. H., Rowley, S., Sahebi, F., Somlo, G., Vogl, D. T., Weisdorf, D., Ewell, M., Wu, J., Geller, N. L., Horowitz, M. M., Giralt, S., and Maloney, D. G., Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial., Lancet Oncol, vol. 12, no. 13, pp. 1195-203, 2011.